Study of Indomethacin Capsules to Treat Pain Following Bunionectomy
NCT ID: NCT01626118
Last Updated: 2014-03-17
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
373 participants
INTERVENTIONAL
2012-05-31
2012-08-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Study of Indomethacin Capsules to Treat Pain Following Bunionectomy
NCT01543685
Study of Diclofenac Capsules to Treat Pain Following Bunionectomy
NCT01462435
A Study of MDT-10013 in the Treatment of Acute Postoperative Pain Following Bunionectomy
NCT02077140
Maxigesic IV Phase 3 Bunionectomy Study
NCT02689063
Placebo-Controlled Evaluation of N1539 Following Bunionectomy Surgery
NCT02540265
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Indomethacin 40 mg TID
Indomethacin
capsules, 40 mg, TID
Indomethacin 40 mg BID
Indomethacin
capsules, 40 mg, BID
Placebo
Placebo
capsules
Indomethacin 20 mg TID
Indomethacin
capsules, 20 mg, TID
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Indomethacin
capsules, 40 mg, TID
Indomethacin
capsules, 40 mg, BID
Indomethacin
capsules, 20 mg, TID
Placebo
capsules
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* For women of child-bearing potential: a woman who is not pregnant and not nursing, and who is practicing an acceptable method of birth control
* Has undergone primary, unilateral, first metatarsal bunionectomy with no additional collateral procedures
* Patient must be willing to stay at the study site ≥ 72 hours
Exclusion Criteria
* Patient has a current disease or history of a disease that will impact the study or the patient's well-being
* Patient has used or intends to use any of the medications that are prohibited by the protocol
* Patient has a history of drug or alcohol abuse or dependence, or patient has a positive urine drug screen or alcohol breathalyzer test
* Patient has taken another investigational drug within 30 days prior to screening
18 Years
65 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Iroko Pharmaceuticals, LLC
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Jason Dickerson, DPM
Role: PRINCIPAL_INVESTIGATOR
Premier Research Group Limited
Michael Golf, DPM
Role: PRINCIPAL_INVESTIGATOR
Premier Research Group Limited
Ira Gottlieb, DPM
Role: PRINCIPAL_INVESTIGATOR
Chesapeake Research Group, LLC
Kyle Patrick, DO
Role: PRINCIPAL_INVESTIGATOR
Premier Research Group Limited
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Premier Research Group Limited
Phoenix, Arizona, United States
Chesapeake Research Group, LLC
Pasadena, Maryland, United States
Premier Research Group Limited
Austin, Texas, United States
Premier Research Group Limited
Salt Lake City, Utah, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
IND3-10-06
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.